Published in:
Open Access
01-12-2011 | Poster presentation
Adverse event reporting in randomised trials of neuropathic pain: challenges for clinical usefulness of safety data
Authors:
Victoria R Cornelius, Odile Sauzet, Salma Ayis, Joy Ross, Paul Farquhar-Smith, Ruth A Branford, John E Williams, Janet L Peacock
Published in:
Trials
|
Special Issue 1/2011
Login to get access
Excerpt
Monitoring the safety of therapies is of paramount importance in protecting patients from harm and enabling risk-benefit assessment. The recording and reporting of measures of efficacy has received considerable attention and while by no means perfect, has advanced further than the parallel assessment of harm. The stimulus for this study came from a commissioned effectiveness and cost-effectiveness review of treatments for neuropathic pain in patients (the CEAN study) [
1]. CEAN noted that the completeness of adverse event (AE) reporting varied between trials and some expert opinion was required where primary data were insufficient for modeling cost-effectiveness. Further, clinicians indicated that trials sometimes failed to provide adequate information for clinical decision-making and informing patients. …
